First Gaucher type 3 neurological drug approved - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

First Gaucher type 3 neurological drug approved

  • By

  • Teraya Smith

  • November 18, 2026

  • 2 min

Share

Objective:

The article examines the objective, findings, and clinical context described in First Gaucher type 3 neurological drug approved.

Approach:
  • Approval: The FDA approved venglustat (Infilbray) for adults and pediatric patients weighing at least 15 kg with GD3.
  • Study: Approval was supported by a randomized, double-blind, multicenter trial of 43 patients aged 12 years or older with GD3 and stable systemic disease after enzyme replacement therapy. Participants received daily oral venglustat or intravenous enzyme replacement t…
  • Assessment: Efficacy was assessed using measures of neurological manifestations, including ataxia and cognitive function.
Key Findings:
  • At week 52, the venglustat group improved on a combined neurological assessment compared with the enzyme replacement therapy group.
  • The FDA announcement did not provide numerical estimates of treatment effects.
  • Frequently reported adverse effects included gastrointestinal symptoms and mood-related changes; serious psychiatric risks, including suicidal ideation and behavior, were also reported.
Interpretation:

Venglustat crosses the blood-brain barrier and inhibits glucosylceramide synthase, reducing glucosphingolipid accumulation. The FDA described it as the first treatment authorized for neurological symptoms of GD3.

Limitations:
  • The trial included 43 patients and followed them for 52 weeks.
  • The FDA announcement did not report numerical treatment-effect estimates.
  • Potential risks identified in animal studies included visual clouding in younger patients and adverse fetal-development effects during pregnancy.
Conclusion:

The FDA granted venglustat Orphan Drug designation and Priority Review.

Sources:

Original Source(s)

Related Content